



# David Yaw Twum-Barima MB, CHB, MSC, FRCPC

Oakville

3075 Hospital Gate, Suite 301, Oakville, ON L6M 1M1, Canada

Tel (905) 337-0040

## CURRICULUM VITAE

### Education, Certification & Licenses

1983-84	Certification & Fellowship, Internal Medicine	Fellow, Royal College of Physicians Canada
1983-84	Sub-specialty Training in Endocrinology and Metabolism	Ottawa Civic Hospital
1979-81	Master of Science	University of Western Ontario
1969-74	Bachelor of Medicine	University of Ghana, Africa

### Professional Activities

2002-present	Associate Endocrinologist	LMC Diabetes & Endocrinology
2002	Emergency Specialty Relief Staff	North York General Hospital, Toronto
1994-02	Chief of Medicine	Quinte Health Care Corporation, Trenton Memorial Site
1992-96	Director, Continued Medical Education	Trenton Memorial Hospital
1989-02	Active Staff, Department of Medicine	Belleville General Hospital
1989-92	Director, Intensive Care Unit	Trenton Memorial Hospital
1985-88	Lecturer, Faculty of Medicine and Endocrinology	University of Manitoba
1984-88	Consultant Internal Medicine and Endocrinology	Winnipeg, Manitoba
1985-88	Consultant, Internal Medicine	Health Sciences Centre, Winnipeg, Manitoba
1985-88	Active Staff	Victoria General Hospital, Winnipeg, Manitoba

### Achievements, Associations & Specialties

Publications	Twum-Barima, Y., A Study of central respiratory effects of four beta-adrenergic blocking drugs: MSc Thesis, University of Western Ontario, April, 1981	
	Twum-Barima, Y., and Carruthers, S. G., Quinidine-Rafampin Interaction. <i>New England Journal of Medicine</i> 304 (24) 1466-1469, 1981	
	Twum-Barima, Y., Ahmad, D., Hamilton, J. T. and Carruthers, S. G., Lack of effect of beta-adrenergic blocking drugs on the hyperventilatory response to carbon dioxide in normal subjects. <i>Clinical Pharmacology and Therapeutics</i> , 32: 289-294, 1982	
	Carruthers SG, Twum-Barima Y, Measurements of Partial Agonist Activity of Pindolol in Man. <i>Clinical Pharmacology &amp; Therapeutics</i> , 30:581-6, 1981	
	Klein, G. J., Twum-Barima, Y., Gulamhusein, S., Carruthers, S.G., Jarvis, R.T. and Doner, A.P., Ph.D. Verapamil in Chronic Atrial Fibrillation: Pharmacokinetics and variable Patterns of Response. <i>Clin. Cardiol.</i> 7, 474-483, 1984	
	Twum-Barima Y, Carruthers SG Assessment of agonist activity of pindolol by evaluation of metoprolol-pindolol interaction. <i>Clin Res</i> 28(3), 667A, 1980	
	Twum-Barima Y, Ahmad D, McCall B, Carruthers SG. Cardiac & respiratory effects of 4 beta-adrenoceptor blocking drugs. <i>Clin Res</i> 28(3) 667A, 1980	
	Awards	Astra Award for Best Presentation by Trainee in Clinical Pharmacology, Canadian Society for Clinical Pharmacology and Therapeutics, 1980
	Memberships	Canadian Diabetes Association (CDA)
		American Diabetes Association (ADA)
The Canadian Society of Endocrinology and Metabolism (CSEM)		

### Clinical Trials & Research Activities

2010-2016	Emerge 7(Roche), GBCF(Lilly), EFC10781(Sanofi-aventis), GBDN(Lilly), DAPA19(AstraZeneca), R331333PAI3027(J&J), SYR-332-305(Takeda), 20080099(Amgen), CLAF2224(Novartis), 1001(Andromeda), CACZ88512207(Novartis), 28431754DIA3010 (J&J), DEFEND-2(Tolerx), H9X-MC-GBDJ(Lilly), DEFEND-1 Ext(Tolerx), 1218.23(BI), DAPA06 Ext(AstraZenca), TAK-875_306(Takeda), BIAJ(Lilly), TAK-875_304(Takeda), EFC12347(Sanofi-aventis), DECLARE(AstraZeneca), MK8835-002 (Merck), NN9211-3919(Novo Nordisk), B1481022(Pfizer), B1481038(Pfizer), B1481045 (Pfizer), J&J 2004 (Janssen Research), CAMELLIA (Eisai), HARMONY 10 (GSK), DERIVE (Astrazeneca) Etc.
2009	SA 10780(Sanofi-aventis), 20080099(Amgen), DEFEND-1(Tolerx), Emerge 6(Roche), CLAF2201(Novartis), TIDE(GSK), 1218.52 (BI), AXON-201(TransTech Pharma), DM 200-101(ConjuChem), 1218.40(BI), 1218.46(BI), SA 6910(Sanofi-aventis), CLAF 2308(Novartis), A5351025(Pfizer), Eprodisate(Bellus Health), CV181-011(BMS), CV181-014(BMS) Etc.
2008	DAPA 06(AstraZeneca), LANTU C 50079(Sanofi-aventis), MARS227 & MARS228(Eisai), ENDORSE(Servier),1218.18(BI), MB102-014(BMS), ALTITUDE(Novartis), NN 1250SIBA(NovoNordisk), FUSE(Pfizer), NERV(J&J), DAPA 013(AstarZeneca), MB102-013(BMS), Etc.
2002-2007	Navigator(Novartis), MK-0431-052(Merck), 1022(Pfizer), CRESCENDO(Sanofi-aventis), RIO DM(Sanofi-aventis), SYR-475-022(Takeda), STABILITY(GSK), AXON 202(TransTech Pharma), P015/MD-11a-10945(Dr. Reddy's), Rio Lipids(Sanofi-aventis), RUTH(Lilly), PO1418(Schering), Etc.